Behcet DiseaseSymptoms, Doctors, Treatments, Advances & More
Learn About Behcet Disease
Behçet disease is an inflammatory condition that affects many parts of the body. The health problems associated with Behçet disease result from widespread inflammation of blood vessels (vasculitis). This inflammation most commonly affects small blood vessels in the mouth, genitals, skin, and eyes.
The cause of Behçet disease is unknown. The condition probably results from a combination of genetic and environmental factors, most of which have not been identified. However, a particular variation in the HLA-B gene has been associated with the risk of developing Behçet disease.
Behçet disease is most common in Mediterranean countries, the Middle East, Japan, and other parts of Asia. However, it has been found in populations worldwide.
Most cases of Behçet disease are sporadic, which means they occur in people with no history of the disorder in their family. A small percentage of all cases have been reported to run in families; however, the condition does not have a clear pattern of inheritance.
Patrice Cacoub practices in Paris, France. Mr. Cacoub is rated as an Elite expert by MediFind in the treatment of Behcet Disease. His top areas of expertise are Cryoglobulinemia, Vasculitis, Takayasu Arteritis, Vitrectomy, and Leg or Foot Amputation.
Gulen Hatemi practices in Cerrahpasa, Turkey. Hatemi is rated as an Elite expert by MediFind in the treatment of Behcet Disease. Their top areas of expertise are Behcet Disease, Mouth Ulcers, Mouth Sores, Uveitis, and Colonoscopy.
Emire Seyahi practices in Istanbul, Turkey. Seyahi is rated as an Elite expert by MediFind in the treatment of Behcet Disease. Their top areas of expertise are Behcet Disease, Uveitis, Vasculitis, and Takayasu Arteritis.
Summary: Behçet disease (BD) is a chronic multisystem inflammatory disorder with a relapsing-remitting course. Pediatric-onset BD is rare and characterized by marked clinical heterogeneity, frequent incomplete presentation at disease onset, and limited availability of pediatric-specific outcome measures and biomarkers. This prospective multicenter study aims to comprehensively characterize the clinical, bi...
Summary: The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
Published Date: June 01, 2017
Published By: National Institutes of Health